TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed performance, with stable gross margins and reduced losses but lowered guidance for 2025, indicating potential challenges. The Q&A highlights uncertainties, particularly with unclear management responses and the need for refinancing and equity raises, suggesting financial strain. Despite some positive growth in Europe and a strong sales force, the lack of precise future growth details and a lowered guidance contribute to a negative sentiment, likely impacting the stock price negatively in the short term.
Key Financial Performance
Revenue $20.7 million for the quarter, representing 9% growth over the prior year. Growth was fueled by stronger adoption across the existing customer base, addition of new accounts, growing demand for OviTex reinforced tissue matrix and OviTex PRS portfolios, and contributions from expanding commercial presence in Europe.
International Sales Grew 9% over the prior period, driven by increased traction in the U.K. and early progress from the commercial launch of the OviTex IHR in Europe.
Gross Margin 68% for the third quarters of both 2025 and 2024, showing no year-over-year change.
Gross Profit $14 million in the third quarter of 2025, compared to $12.9 million in the same period in 2024, reflecting an increase due to higher revenue.
Sales and Marketing Expenses $15.2 million in the third quarter compared to $16.5 million for the prior year period, a decrease mainly due to lower compensation costs, consulting, and travel expenses, offset by higher commission expense on an increased revenue base.
General and Administrative Expenses $3.9 million for the third quarter compared to $3.7 million in the prior year period, showing a slight increase.
R&D Expenses $2.3 million for the third quarter compared to $2.1 million in the prior year period, showing a slight increase.
Total Operating Expenses $21.5 million in the third quarter compared to $22.2 million in the prior year period, and $23.2 million in Q2 2025, reflecting a decrease.
Loss from Operations $7.6 million in the third quarter compared to $9.4 million in the prior year period, showing a reduction in losses.
Net Loss $8.6 million in the third quarter compared to $10.4 million in the prior year period, showing a reduction in losses.
Cash and Cash Equivalents $29.7 million at the end of the third quarter, reflecting cash consumption of $5.7 million in the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OviTex reinforced tissue matrix and OviTex PRS portfolios: Growing demand and contributions from expanding commercial presence in Europe. International sales grew 9% over the prior period, driven by increased traction in the U.K. and early progress from the commercial launch of the OviTex IHR in Europe.
OviTex PRS: Featured in 3 scientific abstract publications, contributing to a growing body of clinical evidence with over 50 published works and ongoing data collection in more than 2,500 patients.
OviTex and OviTex PRS implantations: Surpassed 100,000 implantations globally, highlighting growing impact in the soft tissue repair and reconstruction market.
European market expansion: Advanced awareness through targeted surgeon engagement, including a July Cadaver lab with 30 key surgeons, and progress with the U.K. NHS value-based procurement initiative, securing NHS finance sign-off in September.
U.S. market expansion: Broadened market access by adding 835 hospitals, including diverse health systems and community hospitals.
Sales and marketing efficiency: Improved sales and marketing spend as a percentage of revenue from 89.7% in Q1 to 73.6% in Q3.
Commercial field leadership: Revamped leadership and recruited top medical device representatives, achieving a 2025 budgeted commercial headcount target of 76 territory managers.
Partnership with Advance Medical Solutions: Best revenue quarter for LIQUIFIX with 126% year-over-year growth, driven by enhanced clinical support and collaboration.
Board of Directors: Added Betty Jo Rocchio and Bill Plovanic, bringing expertise in market access strategy, clinical excellence, and MedTech company operations.
Financial strategy: Refinanced and upsized debt facility from $40 million to $60 million and completed a $13 million equity offering, adding $26 million in incremental net cash to the balance sheet.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth: While revenue grew 9% year-over-year, Q3 results were lower than expected, indicating potential challenges in meeting growth expectations.
Sales and Marketing Expenses: Although sales and marketing expenses decreased as a percentage of revenue, they remain significant, which could impact profitability if revenue growth slows.
Cash Consumption: The company consumed $5.7 million in cash during the quarter, and while additional financing was secured, ongoing cash burn could pose a risk to financial stability.
Debt Refinancing: The company increased its debt facility from $40 million to $60 million, which adds financial flexibility but also increases financial obligations.
Market Expansion: While the company expanded its market presence, achieving sustainable growth in new markets like Europe and the U.K. NHS initiative may face challenges due to regulatory and competitive pressures.
Product Adoption: Despite growth in product adoption, the pace of adoption for OviTex PRS was slower (3% unit sales growth), which could impact future revenue.
Operational Efficiency: Efforts to improve operational efficiency are ongoing, but achieving significant cost reductions while maintaining growth could be challenging.
Strategic Execution: The company is undergoing leadership and strategic changes, which, while promising, carry execution risks during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth for 2025: The company expects revenue for the full year 2025 to grow at least 16% over 2024.
Revenue Growth for 2026: Directional expectations for 2026 revenue indicate at least 15% growth from 2025, with further updates to be provided after the budgeting process.
Debt Facility and Financial Resources: The company refinanced and upsized its debt facility from $40 million to $60 million, with an additional $10 million tranche available upon achieving $100 million in trailing 12-month revenues. Additionally, a $13 million equity offering was completed, adding approximately $26 million in incremental net cash to the balance sheet. These measures are expected to provide sufficient financial resources to reach profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the rationale for the debt refinancing and equity raise at this time?
A:The rationale for the debt refinancing was to replace the previous facility, which would have begun amortizing in June 2026, and to potentially upsize it. Additionally, there were inbound requests from investors to support the company, leading to a small equity raise. This resulted in adding about $26 million in net capital on top of the $30 million at the end of the quarter, with a potential $10 million tranche upon hitting revenue targets, ensuring sufficient funds to reach profitability.
Q:Why was the guidance for 2025 lowered, and what are the growth expectations for early 2026?
A:The 2025 guidance was lowered due to the ongoing budgeting process and the need to reset fourth-quarter expectations. The company is confident in achieving 15% growth for 2025, with plans to improve on that through internal budgeting. Early 2026 growth expectations are still being evaluated and will be updated in the next earnings call.
Q:What are the details around the sales force hiring for next year?
A:The company plans to increase the sales force to 90+ territory managers by Q1 2025. They have shortened the time to hire, with some markets completing the process in one day. The focus is on hiring top-tier medical device representatives with strong clinical adaptability and strategic thinking. The current cohort of 50-52 reps has performed well, achieving nearly 100% of their targets, and the company aims to drive growth by expanding this cohort.
Q:What is the breakeven profile in light of recent investments and financing?
A:The breakeven point remains in the high $20 million per quarter range. The company aims to keep operating expenses relatively flat despite sales force growth by drawing from account specialist ranks and improving sales force efficiency. Sales force efficiency has improved from 90% to a little over 70% of sales within three quarters.
Q:What are the growth expectations for 2026, considering increased productivity for reps?
A:Growth in 2026 depends on filling sales force positions with the right talent. The company is giving itself room to ensure proper hiring and will provide updates on 2026 growth expectations in the next earnings call.
Q:What updates are there on the ramp curve for newer classes of sales reps compared to older classes?
A:The company has refined its hiring profile and enhanced training programs, resulting in higher competency scores for new hires. The infrastructure and support network around the field team are expected to drive faster growth and productivity for newer classes of sales reps.
Q:What is baked into the Q4 2025 guidance, and why does it imply minimal sequential growth?
A:The Q4 2025 guidance includes at least 16% year-over-year growth, with potential upside from efficiencies in the sales force and hiring of new reps. The guidance accounts for some turnover in the sales force and recent upgrades in commercial leadership, giving room for adjustments to ensure a strong start to 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on early 2026 growth expectations, stating that it depends on filling sales force positions and that updates will be provided in the next earnings call. Additionally, while discussing Q4 2025 guidance, management used vague language about giving themselves 'room' and did not provide precise data on expected sequential growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMS support
Advance Medical
Bio footprint
Bio step
Cadaver lab
Clinical Hiatal
Conference Instructions
Director progress
Directors Rocchio
ECHO
LIQUIFIX
NHS
PRS
Plastic
UK
adoption
balance sheet
base
capability
culture
debt
demand
experience
expertise
foundation
health
highlight
insight
investment
market access
milestone
month
outcome
presence Europe
publication
representative
side
system
tissue repair
tranche future
TELA Transcript
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reveals strong financial performance with a 25% YoY revenue increase and improved gross margins. Despite regulatory and market challenges, the company shows resilience with reduced net loss and strategic initiatives for product development. The lack of guidance or shareholder return details is a concern, but the financial metrics and growth potential in Europe suggest a positive outlook. The stock price is likely to experience a positive movement of 2% to 8% over the next two weeks, assuming a neutral market cap impact.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reflects mixed signals. While there are improvements in losses and cash flexibility, the reduced guidance and uncertainties due to organizational changes and external factors like weather impact sentiment negatively. The Q&A highlighted management's cautious approach and lack of clarity in some responses, further contributing to a neutral outlook. The absence of strong positive catalysts or partnerships limits the potential for a significant stock price increase.
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed performance, with stable gross margins and reduced losses but lowered guidance for 2025, indicating potential challenges. The Q&A highlights uncertainties, particularly with unclear management responses and the need for refinancing and equity raises, suggesting financial strain. Despite some positive growth in Europe and a strong sales force, the lack of precise future growth details and a lowered guidance contribute to a negative sentiment, likely impacting the stock price negatively in the short term.
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call indicates strong financial performance with reduced losses and consistent sales growth. The Q&A section supports this with plans for sales force expansion and strategic focus on new product launches and market positioning. Despite some expenses rising, the overall financial health appears stable. Additionally, management's confidence in meeting guidance and increased focus on patient-centric culture and reinforced tissue matrix contracts suggest positive future prospects. The lack of any major risks or uncertainties in management responses further supports a positive sentiment.
TELA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
